Diligence memo · auto-generated · as of July 2, 2026

Synergy Biomedical, LLC

Synergy Biomedical, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Synergy Biomedical, LLC operates in Biotechnology, based in COLLEGEVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Synergy Biomedical, LLC has raised $1.2M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $612K on 2014-02-18.

Most recent recorded round closed around 2014-02-18.

Valuation (modeled)modeled

Provath models Synergy Biomedical, LLC at approximately $34M (range $326K–$383M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.13× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 15 months.

Last raise 12.4 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.5× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 21% of Biotechnology peers (4293 compared).

Modeled value ranks above 38% of those peers.

Closest niche peers: Imanis Life Sciences, LLC, Truminim, LLC, Direct Spinal Therapeutics, Inc., Universal Biosensors Inc, One World Lab, Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.